Regulatory
MEDIUMTrigger: Any delay or rejection in the demerger scheme would defer the INR 25,000 Cr revenue target for Apollo Healthtech and the capital unlock from listing the pharmacy/digital health business
Monitor: regulatory
Apollo Hospitals Enterprise Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +14.6%Average12w Streak
In , Apollo Hospitals Enterprise Ltd (Hospitals) is outperforming Nifty 500 with +14.6% relative strength. Fundamentals: Average. On a 12-week streak.
Apollo Hospitals Enterprise Ltd Key Facts
- PE Ratio
- 64.1x
- Market Cap
- ₹1,16,422 Cr
- PAT Growth YoY
- +36%
- Revenue Growth YoY
- +17%
- OPM
- 15.0%
- RS vs Nifty 500
- +14.6%
PE: Cycle BottomStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
👔Promoter stake down 1.3% this quarter
🌐FII stake decreased 1.2% this quarter
🏛️DII accumulation — stake up 1.2%
💰Trading 10% above estimated fair value
Key Risks
1. Regulatory
MEDIUM2. Geopolitical
MEDIUM3. Regulatory
LOWKey Numbers
PAT Growth YoY
+36%
Stable
Revenue YoY
+17%
Stable
Operating Margin
15.0%
+100 bps YoY
PE Ratio
64.1
Current Price
₹8,097
Dividend Yield
0.23%
Fundamental Score
49/100
Average
3Y PAT CAGR
+11%
Market Cap
1.2L Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for Apollo Hospitals Enterprise Ltd?
Earnings deceleration risks from management commentary
Geopolitical
MEDIUMTrigger: Bangladesh political situation remains unresolved; partial recovery even to 15-20% share would be a meaningful ARPP and margin tailwind given high-complexity cases in this cohort
Monitor: geopolitical
Regulatory
LOWTrigger: Revenue recognition deferral is an accounting/GST timing issue, not a demand or competitive issue — does not change long-term digital health trajectory
Monitor: regulatory
Labor
MEDIUMTrigger: Hospital ramp-up requires hiring clinical staff, credentialing, and building referral networks — all time-consuming; Morgan Stanley cut EPS estimates 2.5-3% for FY27-28 on this basis
Monitor: labor
Logistics
LOWTrigger: Pharmaceutical distribution is margin-thin (7-8% EBITDA target) and scale-dependent; integration execution risk is the key variable
Monitor: logistics
What Is Apollo Hospitals Enterprise Ltd's Management Saying?
Key quotes from recent conference calls
“The tribunal approved revised meeting dates for creditors and shareholders while dismissing the application for dispensation of secured creditors meeting despite 90.96% consent [Risk (regulatory): MEDIUM]”
“In early 2024, Bangladeshi patients accounted for approximately 30% of Apollo's international patient portfolio. However, during Q3FY26, this share plummeted to just 7-8% [Risk (geopolitical): MEDIUM]”
“The moderation is due to changes in revenue recognition, particularly in the insurance business, which has deferred revenue recognition over the next 12 months. We expect to achieve cash EBITDA break-even by Q1 of FY27 [Risk (regulatory): LOW]”
“The company anticipates a cost headwind of INR 150 crore due to the ramp-up of new hospitals. There will be some startup losses, but we aim to offset these through volume and revenue growth in existing hospitals [Risk (labor): MEDIUM]”
How Fast Is Apollo Hospitals Enterprise Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | +14% | Stable |
| PAT (Net Profit) | +36% | +11% | Stable |
| OPM | 15.0% | +100 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Hospitals Stocks Beating Nifty 500
Frequently Asked Questions: Apollo Hospitals Enterprise Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Apollo Hospitals Enterprise Ltd's latest quarterly results?
Apollo Hospitals Enterprise Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +36.1% (stable)
- Revenue Growth YoY: +17.2%
- Operating Margin: 15.0% (expanding)
Is Apollo Hospitals Enterprise Ltd's profit growing or declining?
Apollo Hospitals Enterprise Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +36.1% (latest quarter)
- PAT Growth QoQ: +4.5% (sequential)
- 3-Year PAT CAGR: +10.8%
- Trend: Stable — consistent growth pattern
What is Apollo Hospitals Enterprise Ltd's revenue growth trend?
Apollo Hospitals Enterprise Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +17.2%
- Revenue Growth QoQ: +2.7% (sequential)
- 3-Year Revenue CAGR: +14.1%
How is Apollo Hospitals Enterprise Ltd's operating margin trending?
Apollo Hospitals Enterprise Ltd's operating margin is expanding.
- Current OPM: 15.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Apollo Hospitals Enterprise Ltd's 3-year profit and revenue CAGR?
Apollo Hospitals Enterprise Ltd's long-term compounding rates
- 3-Year Profit CAGR: +10.8%
- 3-Year Revenue CAGR: +14.1%
Is Apollo Hospitals Enterprise Ltd's growth accelerating or decelerating?
Apollo Hospitals Enterprise Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: +11.4% bps
- Sequential Acceleration: -7.5% bps
What is Apollo Hospitals Enterprise Ltd's trailing twelve month (TTM) performance?
Apollo Hospitals Enterprise Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹2,000 Cr
- TTM PAT Growth: +38.3% YoY
- TTM Revenue: ₹24,000 Cr
- TTM Revenue Growth: +14.5% YoY
- TTM Operating Margin: 14.8%
Is Apollo Hospitals Enterprise Ltd overvalued or undervalued?
Apollo Hospitals Enterprise Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 64.1x
- Price-to-Book: 12.8x
What is Apollo Hospitals Enterprise Ltd's current PE ratio?
Apollo Hospitals Enterprise Ltd's current PE ratio is 64.1x.
- Current PE: 64.1x
- Market Cap: 1.2 Lakh Cr
- Dividend Yield: 0.23%
How does Apollo Hospitals Enterprise Ltd's valuation compare to its history?
Apollo Hospitals Enterprise Ltd's current PE is 64.1x.
- Current PE: 64.1x
- Valuation Assessment: Overvalued
What is Apollo Hospitals Enterprise Ltd's price-to-book ratio?
Apollo Hospitals Enterprise Ltd's price-to-book ratio is 12.8x.
- Price-to-Book (P/B): 12.8x
- Book Value per Share: ₹632
- Current Price: ₹8097
Is Apollo Hospitals Enterprise Ltd a fundamentally strong company?
Apollo Hospitals Enterprise Ltd is rated Average with a fundamental score of 49.32/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +17.2% (10% weight)
- PAT Growth YoY: +36.1% (10% weight)
- PAT Growth QoQ: +4.5% (10% weight)
- Margins expanding (10% weight)
Is Apollo Hospitals Enterprise Ltd debt free?
Apollo Hospitals Enterprise Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹8,000 Cr
What is Apollo Hospitals Enterprise Ltd's return on equity (ROE) and ROCE?
Apollo Hospitals Enterprise Ltd's return ratios over recent years
- FY2023: ROCE 14.0%
- FY2024: ROCE 15.0%
- FY2025: ROCE 17.0%
Is Apollo Hospitals Enterprise Ltd's cash flow positive?
Apollo Hospitals Enterprise Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹2,000 Cr
- Free Cash Flow (FCF): ₹-1,000 Cr
- CFO/PAT Ratio: 142% (strong cash conversion)
What is Apollo Hospitals Enterprise Ltd's dividend yield?
Apollo Hospitals Enterprise Ltd's current dividend yield is 0.23%.
- Dividend Yield: 0.23%
- Current Price: ₹8097
Who holds Apollo Hospitals Enterprise Ltd shares — promoters, FII, DII?
Apollo Hospitals Enterprise Ltd's shareholding pattern (Mar 2026)
- Promoters: 28.0%
- FII (Foreign): 42.6%
- DII (Domestic): 22.8%
- Public: 6.4%
Is promoter holding increasing or decreasing in Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 28.0% (Mar 2026)
- Previous Quarter: 28.0% (Dec 2025)
- Change: 0.00% (stable)
How long has Apollo Hospitals Enterprise Ltd been outperforming Nifty 500?
Apollo Hospitals Enterprise Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Is Apollo Hospitals Enterprise Ltd a new momentum entry or an established outperformer?
Apollo Hospitals Enterprise Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
What are the key risks in Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd has 5 key risks worth monitoring
- [MEDIUM] Regulatory — Any delay or rejection in the demerger scheme would defer the INR 25,000 Cr revenue target for Apollo Healthtech and the capital unlock from listing the pharmacy/digital health business
- [MEDIUM] Geopolitical — Bangladesh political situation remains unresolved; partial recovery even to 15-20% share would be a meaningful ARPP and margin tailwind given high-complexity cases in this cohort
- [LOW] Regulatory — Revenue recognition deferral is an accounting/GST timing issue, not a demand or competitive issue — does not change long-term digital health trajectory
- [MEDIUM] Labor — Hospital ramp-up requires hiring clinical staff, credentialing, and building referral networks — all time-consuming; Morgan Stanley cut EPS estimates 2.5-3% for FY27-28 on this basis
What did Apollo Hospitals Enterprise Ltd's management say in the latest earnings call?
In Q3 FY26, Apollo Hospitals Enterprise Ltd's management highlighted
- "The tribunal approved revised meeting dates for creditors and shareholders while dismissing the application for dispensation of secured creditors meet..."
- "In early 2024, Bangladeshi patients accounted for approximately 30% of Apollo's international patient portfolio. However, during Q3FY26, this share pl..."
- "The moderation is due to changes in revenue recognition, particularly in the insurance business, which has deferred revenue recognition over the next ..."
Is Apollo Hospitals Enterprise Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Apollo Hospitals Enterprise Ltd may be worth studying
- Earnings growing at +36.1% YoY
- Operating margins are expanding — OPM at 15.0%
- Cash flow is positive — CFO ₹2,000 Cr
What is the investment thesis for Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +17.2% YoY
- Margins expanding
Risk Factors (Bear Case)
- Appears overvalued
- Key risk: Regulatory
What is the future outlook for Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Overvalued
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.